Waters receives FDA clearance for lymphoma diagnostic tests

Waters Corporation (WAT) announced FDA 510(k) clearance for two BD OneFlow tests, BD OneFlow LST and BD OneFlow B-CLPD T1, for identifying B-cell non-Hodgkin lymphoma. The tests showed 96.3% sensitivity and 98.2% specificity in detecting CLL. The system aims to improve efficiency and consistency in flow cytometry testing. Preorders are open, with a U.S. launch planned for spring 2027. WAT shares are currently trading at $475.21, down 0.31%.

Waters Corporation (NYSE: WAT) announced FDA 510(k) clearance for its BD OneFlow LST and BD OneFlow B-CLPD T1 Tests, which aid in diagnosing B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The tests offer 96.3% sensitivity and 98.2% specificity. They reduce manual steps, improving workflow efficiency and reducing errors. The tests will be commercially available in the U.S. in spring 2027.

Waters Corporation (NYSE: WAT) acquired MOBILion Systems, a developer of high-resolution ion mobility separation tech, to expand its proteomics market presence. The deal adds MOBILion's SLIM tech to Waters' mass spectrometry portfolio, aiming to enhance proteome coverage, sensitivity, and throughput. Waters estimates the proteomics market at $2B with high single-digit annual growth. The acquisition supports AI-driven research and potential clinical applications.

Bernstein raised its price target on Waters Corp. (WAT) to $535 from $450, citing strong Q3 2026 results. Revenue grew 10% in constant currency, and adjusted EPS of $4.10 beat estimates. The company raised full-year 2026 guidance for revenue and EPS. Bernstein described the 2027 outlook as conservative, with mid-single-digit-plus organic growth expected. Other analysts also raised price targets following the earnings beat.

KeyBanc raised its price target for Waters Corp. (WAT) to $500 from $460, citing strong Q3 results and raised guidance. WAT reported 10% revenue growth and 30.1% adjusted operating margin, exceeding estimates. The stock is up 52% in six months, trading near $460. Stifel also raised its target to $470 but maintained a Hold rating. WAT's full-year guidance was increased to 9.1%-9.7% growth, with AI and China growth cited as positive factors.

Waters Corporation reported Q3 2026 revenue of $1.767B, up from $1.677B YoY. Analytical Sciences Division grew 8% to $703M, driven by LC-MS demand. The company acquired MOBILion Systems to expand its proteomics portfolio. Waters raised full-year guidance, expecting 9.1%-9.7% organic revenue growth. CEO Udit Batra cited strong execution and new products as growth drivers.